The latest price target for Matinas BioPharma Hldgs (AMEX:MTNB) was reported by Maxim Group on October 31, 2024. The analyst firm set a price target for $0.00 expecting MTNB to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Matinas BioPharma Hldgs (AMEX:MTNB) was provided by Maxim Group, and Matinas BioPharma Hldgs downgraded their hold rating.

There is no last upgrade for Matinas BioPharma Hldgs

The last downgrade for Matinas BioPharma Holdings Inc happened on October 31, 2024 when Maxim Group changed their price target from N/A to N/A for Matinas BioPharma Holdings Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Matinas BioPharma Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Matinas BioPharma Hldgs was filed on October 31, 2024 so you should expect the next rating to be made available sometime around October 31, 2025.

While ratings are subjective and will change, the latest Matinas BioPharma Hldgs (MTNB) rating was a downgraded with a price target of $0.00 to $0.00. The current price Matinas BioPharma Hldgs (MTNB) is trading at is $0.57, which is out of the analyst’s predicted range.